{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent&page=16", "query": { "condition": "Recurrent", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 9639, "total_pages": 964, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T18:04:13.266Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02094872", "title": "Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IIIA Melanoma", "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "cytology specimen collection procedure", "type": "OTHER" }, { "name": "MEK 162 therapy or molecularly targeted therapy", "type": "DRUG" }, { "name": "therapeutic procedure", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2014-05", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2020-01-02", "last_synced_at": "2026-10-17T18:04:13.266Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02094872" }, { "nct_id": "NCT04636775", "title": "Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "NSCLC Stage IV", "NSCLC, Recurrent" ], "interventions": [ { "name": "Microbiome", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Jun Zhang, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2020-07-29", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2023-12-11", "last_synced_at": "2026-10-17T18:04:13.266Z", "location_count": 3, "location_summary": "Fairway, Kansas • Kansas City, Kansas", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04636775" }, { "nct_id": "NCT00004901", "title": "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "ethynyluracil", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "hydroxyurea", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Robert H. Lurie Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-10", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-10-17T18:04:13.266Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004901" }, { "nct_id": "NCT00053222", "title": "Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2003-02", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2013-09-05", "last_synced_at": "2026-10-17T18:04:13.266Z", "location_count": 11, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "LaGrange", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053222" }, { "nct_id": "NCT05039281", "title": "Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Glioblastoma", "Recurrent Gliosarcoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2022-09-23", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-17T18:04:13.266Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05039281" }, { "nct_id": "NCT00002534", "title": "Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "low-LET electron therapy", "type": "RADIATION" }, { "name": "low-LET photon therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "1993-05", "completion_date": "2003-04", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-10-17T18:04:13.266Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002534" }, { "nct_id": "NCT00003514", "title": "Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Merkel Cell Carcinoma", "Islet Cell Carcinoma", "Neuroendocrine Carcinoma", "Pituitary Tumor" ], "interventions": [ { "name": "antineoplaston A10", "type": "DRUG" }, { "name": "antineoplaston AS2-1", "type": "DRUG" }, { "name": "alternative product therapy", "type": "PROCEDURE" }, { "name": "biological therapy", "type": "PROCEDURE" }, { "name": "biologically based therapies", "type": "PROCEDURE" }, { "name": "cancer prevention intervention", "type": "PROCEDURE" }, { "name": "complementary and alternative therapy", "type": "PROCEDURE" }, { "name": "differentiation therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Burzynski Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-10-17T18:04:13.266Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003514" }, { "nct_id": "NCT07723248", "title": "A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "Rinzimetostat", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ORIC Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 600, "start_date": "2026-08-03", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-17T18:04:13.266Z", "location_count": 11, "location_summary": "Coral Springs, Florida • Jeffersonville, Indiana • Holland, Michigan + 8 more", "locations": [ { "city": "Coral Springs", "state": "Florida" }, { "city": "Jeffersonville", "state": "Indiana" }, { "city": "Holland", "state": "Michigan" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07723248" }, { "nct_id": "NCT04745234", "title": "Mogamulizumab Q4week Dosing in Participants With R/R CTCL", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous T-Cell Lymphoma, Relapsed", "Cutaneous T-Cell Lymphoma Refractory" ], "interventions": [ { "name": "Mogamulizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-08-16", "completion_date": "2025-05", "has_results": false, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-17T18:04:13.266Z", "location_count": 7, "location_summary": "Duarte, California • Irvine, California • Stanford, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04745234" }, { "nct_id": "NCT04065438", "title": "Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Focal Segmental Glomerulosclerosis" ], "interventions": [ { "name": "LIPOSORBER® LA-15", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Kaneka Medical America LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 35, "start_date": "2020-01-01", "completion_date": "2029-09-30", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-17T18:04:13.266Z", "location_count": 10, "location_summary": "Loma Linda, California • Wilmington, Delaware • Grand Rapids, Michigan + 5 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04065438" } ] }